- Home
- Signaling Pathways
- Metabolism
- PDE
- Anagrelide HCl
Anagrelide HCl
Anagrelide is a selective thrombocytopenic agent [1].
Anagrelide is a FDA-approved drug for the treatment of essential thrombocythemia. It is originally identified as a potential inhibitor of platelet aggregation. Anagrelide selectively affects thrombocytes while shows no significant effect on white blood cells, erythrocytes, or coagulation. Anagrelide is revealed to be available in 0.5mg capsules for oral administration.
Anagrelide is a potent inotropic agent for dogs with remarkable vasodilatory activity. Additionally, anagrelide can reduce renal blood flow. Furthermore, anagrelide has shown to play roles in other chronic myeloproliferative disorders, such as polycythemia vera, chronic myeloid leukemia and agnogenic myeloid metaplasia. Anagrelide has some side effects involving headache, diarrhea, edema, palpitations, and abdominal pain [1].
References:
[1] Oertel MD. Anagrelide, a selective thrombocytopenic agent. Am J Health Syst Pharm. 1998 Oct 1;55(19):1979-86.
Physical Appearance | A solid |
Storage | Store at -20°C |
M.Wt | 292.55 |
Cas No. | 58579-51-4 |
Formula | C10H8Cl3N3O |
Solubility | insoluble in EtOH; insoluble in H2O; ≥4.9 mg/mL in DMSO |
Chemical Name | 6,7-dichloro-5,10-dihydro-3H-imidazo[2,1-b]quinazolin-2-one;hydrochloride |
SDF | Download SDF |
Canonical SMILES | C1C2=C(C=CC(=C2Cl)Cl)NC3=NC(=O)CN31.Cl |
Shipping Condition | Small Molecules with Blue Ice, Modified Nucleotides with Dry Ice. |
General tips | We do not recommend long-term storage for the solution, please use it up soon. |
Quality Control & MSDS
- View current batch: